spacer
home > epc > winter 2009 > the key to tqt
PUBLICATIONS
European Pharmaceutical Contractor

The Key to TQT

 

During the early stages of clinical development, the ability of new drugs to delay cardiac repolarisation is of key concern. As a result, dedicated clinical pharmacology studies designed to examine the effects on cardiac repolarisation have become increasingly important to the pharmaceutical industry and are today an integral component in the development of new chemical entities (NCEs) and ongoing drug development programmes for new drug submissions. These studies, known as ‘thorough QT/QTc studies’ (TQT), are now so significant that they can determine the course, and indeed the viability, of an entire drug development programme.

The first governing body to issue guidance in the form of a ‘Points to Consider’ document was the European Agency for the Evaluation of Medicinal Products (EMEA) in 1997. More recent regulatory guidance for TQT analysis has raised new considerations and challenges when designing drug development programmes. The successful completion of a TQT study in the digital ECG era is highly dependent upon superior technology and efficient, predefined processes to properly manage ECGs.

THE KEY ELEMENTS TO A SUCCESSFUL TQT STUDY

TQT studies came to prominence in order to give an early indication of QT prolongation in human subjects, as a signal of the potential of Torsades de Pointes (TdP). Through a reduction in cost by an appropriate and equal emphasis on the three key elements of these studies, TQT studies could more regularly be conducted at a much earlier stage of development of a NCE. If this were to occur, the resulting signal, positive or negative, will help shape the further development of a compound, rather than just being a regulatory necessity. The key elements to achieve a successful TQT study are:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Asif Naseem has worked as a Medical Writer in both the medical communication agency and clinical research organisation settings. He has been involved in academic science and pharmacology in particular for over eight years. Asif currently specialises in generating clinical study protocols, clinical study reports and related material for a number of Phase I clinical trials performed at Richmond Pharmacology. Additionally, he is involved in the development and generation of posters for conferences and primary manuscripts for publication.

Keith Berelowitz has worked in both the academic and commercial environment of scientific research for more than 10 years. As Director of Operations for Richmond Pharmacology, Keith is responsible for coordinating the integration of employees and processes related to the efficient conduct of early phase clinical trials. Before taking on his current role, Keith was responsible for the recruitment of healthy and patient volunteers for early phase clinical trials (including TQT studies) at Richmond Pharmacology.

Dr Jörg Täubel is a medical practitioner and Managing Director of Richmond Pharmacology, which he co-founded in 2001. He has worked in pharmacology for nearly 20 years and during that time has conducted more than 400 early phase studies in patient, paediatric and healthy volunteers. His experience ranges from first-in-human to proof of concept studies. His particular interests are in cardiology, neurology, gastroenterology, bridging and thorough QT studies.

spacer
Asif Naseem
spacer
spacer
spacer
Keith Berelowitz
spacer
spacer
spacer
Jörg Täubel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement